Exploring Perceptions and Practices Regarding Adult Vaccination against Seasonal Influenza, Tetanus, Pneumococcal Disease, Herpes Zoster and COVID-19: A Mixed-Methods Study in Greece.

Exploring Perceptions and Practices Regarding Adult Vaccination against Seasonal Influenza, Tetanus, Pneumococcal Disease, Herpes Zoster and COVID-19: A Mixed-Methods Study in Greece.

Publication date: Jan 12, 2024

We aimed to document vaccination coverage for five vaccines, predictors of each vaccine’s uptake and attitudes regarding adult vaccination. Adults visiting four pharmacies were randomly invited to participate during summer 2022. Among 395 participants (mean age 51. 2 years, range 19-96), vaccination rates were 78. 1% for influenza and 25. 8% for herpes zoster (≥60 years old), 64. 3% for pneumococcal disease (≥65 years old), 33. 1% for tetanus, while 11. 4% had received two and 74. 8% ≥3 COVID-19 vaccine doses. Half of participants (50. 1%) voiced some degree of hesitancy, and 1. 3% were refusers. The strongest predictor of each vaccine’s uptake was doctor’s recommendation (OR range 11. 33-37. 66, p < 0. 001) and pharmacist's recommendation (4. 01-19. 52, p < 0. 05), except for the COVID-19 vaccine, where the Attitude Towards Adult VACcination (ATAVAC) value of adult vaccination subscale's score was the only predictor (OR: 5. 75, p < 0. 001). Regarding insufficient coverage, thematic content analysis revealed seven main themes. Insufficient knowledge, the absence of health professionals' recommendation, perception of low susceptibility to disease, negligence and dispute of vaccine effectiveness were universal themes, whereas safety concerns and distrust in authorities were reported solely for COVID-19 vaccination. Designing public interventions aiming to increase trust in adult vaccination is essential in the aftermath of the COVID-19 pandemic. Health professionals' role in recommending strongly adult vaccination is crucial.

Open Access PDF

Concepts Keywords
Basel adult vaccination
Greece COVID-19
Pandemic Greece
Vaccination herpes zoster vaccine
influenza vaccine
mixed methods
pneumococcal vaccine
predictors
tetanus vaccine
vaccine hesitancy

Semantics

Type Source Name
disease VO vaccination
disease VO Optaflu
disease MESH Influenza
disease MESH Tetanus
disease MESH Pneumococcal Disease
disease MESH Herpes Zoster
disease MESH COVID-19
disease VO document
disease VO vaccination coverage
disease VO vaccine
disease VO COVID-19 vaccine
disease IDO susceptibility
disease VO vaccine effectiveness
drug DRUGBANK Coenzyme M
disease VO effective
disease VO immunization
disease MESH vaccine preventable diseases
disease VO population
drug DRUGBANK Pentaerythritol tetranitrate
disease VO time
disease VO effectiveness
drug DRUGBANK Trestolone
disease MESH aids
disease MESH educational level
disease MESH marital status
disease IDO history
disease VO vaccinated
disease VO dose
disease VO unvaccinated
disease VO ANOVA
disease MESH Chronic conditions
disease MESH Hypertension
disease MESH Asthma
pathway KEGG Asthma
disease MESH Diabetes mellitus
disease MESH Heart failure
disease MESH Malignancy
disease MESH Hypercholesterolemia
disease MESH Autoimmune diseases
disease MESH complications
disease MESH allergic reactions
drug DRUGBANK Tropicamide
disease MESH Men 3
disease VO p60
disease MESH thrombosis
drug DRUGBANK Methionine
disease VO influenza vaccines

Original Article

(Visited 1 times, 1 visits today)